Quantum Biopharma Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Quantum Biopharma
Pharmaceutical Preparations, SIC 2834
Quantum BioPharma Ltd. is a biopharmaceutical company engaged in the research and development of drug candidates for neurodegenerative diseases and alcohol misuse, as well as functional beverages. Its core clinical pipeline features Lucid-MS (Lucid-21-302), a product candidate targeted at preventing and reversing myelin degradation in the treatment of multiple sclerosis. The company also advances treatments for alcohol misuse and holds rights to related commercial technologies. Its customer base and commercial target audience include healthcare systems, physicians, patients, healthcare payors, and retail consumers who purchase its functional beverage products through commercial distribution partners.
The company operates internationally, conducting business activities, clinical studies, and strategic partnerships across Canada, the United States, and Australia. Corporate administration and executive management operate out of its principal executive offices in Toronto, Ontario, Canada.
Summary of the business section of Quantum Biopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Quantum Biopharma Ltd.
- Headquarters
- Toronto, Ontario, Canada
- Address
- 1 Adelaide Street East, Suite 801 M5C 2V9
- Phone
- (416) 854-8884
- Website
- quantumbiopharma.com
- Employees
- 7, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A6
- Fiscal year ends
- December 31
- Auditor
- MNP LLP, Mississauga, Canada
Stock & identifiers
- Ticker
- QNTM
- Exchange
- Nasdaq
- IPO date
- Jun 8, 2018
- Shares outstanding
- 4M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-65 reverse, Mar 28, 2025; 1-for-65 reverse, Aug 15, 2024; 1-for-201 reverse, Oct 16, 2019
- SEC CIK
- 1771885
- CUSIP
- 74764Y205
- ISIN
- US74764Y2054
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Quantum Biopharma's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 7 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 15, 2024 | Name change | Name changed from FSD Pharma Inc. to Quantum Biopharma Ltd. |